CD274 and small cell lung carcinoma: Specifically, limited response rates to ICI monotherapy have been reported in extensive-stage SCLC, ranging from 2.3% for monotherapy with the anti-PD-L1 antibody atezolizumab to 9.5% for monotherapy with the anti-PD-L1 antibody durvalumab (20, 21).